|
1
|
Ross R: Atherosclerosis - an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee GY, Kim JH, Oh GT, Lee BH, Kwon IC and
Kim IS: Molecular targeting of atherosclerotic plaques by a
stabilin-2-specific peptide ligand. J Control Release. 155:211–217.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu H and Daugherty A: Atherosclerosis.
Arterioscler Thromb Vasc Biol. 35:485–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vanhoutte PM: Endothelial dysfunction: The
first step toward coronary arteriosclerosis. Circ J. 73:595–601.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fukuhara A, Matsuda M, Nishizawa M, Segawa
K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T,
Murakami H, et al: Visfatin: A protein secreted by visceral fat
that mimics the effects of insulin. Science. 307:426–430. 2005.
View Article : Google Scholar
|
|
6
|
Takebayashi K, Suetsugu M, Wakabayashi S,
Aso Y and Inukai T: Association between plasma visfatin and
vascular endothelial function in patients with type 2 diabetes
mellitus. Metabolism. 56:451–458. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dahl TB, Yndestad A, Skjelland M, Øie E,
Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, et
al: Increased expression of visfatin in macrophages of human
unstable carotid and coronary atherosclerosis: Possible role in
inflammation and plaque destabilization. Circulation. 115:972–980.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Auguet T, Aragonès G, Guiu-Jurado E,
Berlanga A, Curriu M, Martinez S, Alibalic A, Aguilar C, Camara ML,
Hernández E, et al: Adipo/cytokines in atherosclerotic secretomes:
Increased visfatin levels in unstable carotid plaque. BMC
Cardiovasc Disord. 16:1492016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moschen AR, Kaser A, Enrich B, Mosheimer
B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine
with proinflammatory and immunomodulating properties. J Immunol.
178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wan Q, Cui X, Shao J, Zhou F, Jia Y, Sun
X, Zhao X, Chen Y, Diao J and Zhang L: Beijing ambient particle
exposure accelerates atherosclerosis in ApoE knockout mice by
upregulating visfatin expression. Cell Stress Chaperones.
19:715–724. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou F, Pan Y, Huang Z, Jia Y, Zhao X,
Chen Y, Diao J, Wan Q and Cui X: Visfatin induces cholesterol
accumulation in macrophages through up-regulation of scavenger
receptor-A and CD36. Cell Stress Chaperones. 18:643–652. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin CF, Chang YH, Liu JC, Chuang MT and
Chien LN: Statin use associated with a reduced risk of pneumonia
requiring hospitalization in patients with myocardial infarction: A
nested case-control study. BMC Cardiovasc Disord. 16:242016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, He C, Wang J, Li X, Yang Z, Sun X,
Fang L and Liu N: Berberine activates peroxisome
proliferator-activated receptor gamma to increase atherosclerotic
plaque stability in Apoe(−/−) mice with hyperhomocysteinemia. J
Diabetes Investig. 7:824–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen FL, Yang ZH, Liu Y, Li LX, Liang WC,
Wang XC, Zhou WB, Yang YH and Hu RM: Berberine inhibits the
expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated
macrophages through PPARgamma pathway. Endocrine. 33:331–337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fan X, Wang J, Hou J, Lin C, Bensoussan A,
Chang D, Liu J and Wang B: Berberine alleviates ox-LDL induced
inflammatory factors by up-regulation of autophagy via AMPK/mTOR
signaling pathway. J Transl Med. 13:922015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Z, Wang L, Meng S, Wang Y, Chen T
and Wang C: Berberine reduces both MMP-9 and EMMPRIN expression
through prevention of p38 pathway activation in PMA-induced
macrophages. Int J Cardiol. 146:153–158. 2011. View Article : Google Scholar
|
|
17
|
Zimetti F, Adorni MP, Ronda N, Gatti R,
Bernini F and Favari E: The natural compound berberine positively
affects macrophage functions involved in atherogenesis. Nutr Metab
Cardiovasc Dis. 25:195–201. 2015. View Article : Google Scholar
|
|
18
|
Zhang SH, Reddick RL, Piedrahita JA and
Maeda N: Spontaneous hypercholesterolemia and arterial lesions in
mice lacking apolipoprotein E. Science. 258:468–471. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goon PK, Watson T, Shantsila E, Boos CJ
and Lip GY: Standardization of circulating endothelial cell
enumeration by the use of human umbilical vein endothelial cells. J
Thromb Haemost. 5:870–872. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whitman SC: A practical approach to using
mice in atherosclerosis research. Clin Biochem Rev. 25:81–93.
2004.
|
|
21
|
Varma V, Yao-Borengasser A, Rasouli N,
Bodles AM, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ III,
McGehee RE Jr, et al: Human visfatin expression: Relationship to
insulin sensitivity, intramyocellular lipids, and inflammation. J
Clin Endocrinol Metab. 92:666–672. 2007. View Article : Google Scholar
|
|
22
|
Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y
and Zhang W: Increased serum visfatin in patients with metabolic
syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf).
69:878–884. 2008. View Article : Google Scholar
|
|
23
|
El-Shishtawy SH, Mosbah O, Sherif N,
Metwaly A, Hanafy A and Kamel L: Association between serum visfatin
and carotid atherosclerosis in diabetic and non-diabetic patients
on maintenance hemodialysis. Electron Physician. 8:1966–1972. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi KL, Qian JY, Qi L, Mao DB, Chen Y, Zhu
Y and Guo XG: Atorvastatin antagonizes the visfatin-induced
expression of inflammatory mediators via the upregulation of NF-κB
activation in HCAECs. Oncol Lett. 12:1438–1444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Li B, Liu Y, Meng H, Wang B, Qi J,
Zhang T, Li H, Zhao T, Sun PH, et al: Visfatin destabilizes
atherosclerotic plaques in apolipoprotein E-deficient mice. PLoS
One. 11:e01482732016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao XN, Li YN and Wang YT: Interleukin-4
regulates macrophage polarization via the MAPK signaling pathway to
protect against atherosclerosis. Genet Mol Res. 15:2016.
|
|
27
|
Zhang Y, Mu Q, Zhou Z, Song H, Zhang Y, Wu
F, Jiang M, Wang F, Zhang W, Li L, et al: Protective effect of
irisin on atherosclerosis via suppressing oxidized low density
lipoprotein induced vascular inflammation and endothelial
dysfunction. PLoS One. 11:e01580382016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yin X, Zhou L, Han F, Han J, Zhang Y, Sun
Z, Zhao W, Wang Z and Zheng L: Beta-adrenoceptor activation by
norepinephrine enhances lipopolysaccharide-induced matrix
metallopro-teinase-9 expression through the ERK/JNK-c-Fos pathway
in human THP-1 cells. J Atheroscler Thromb. 24:55–67. 2016.
View Article : Google Scholar
|
|
29
|
Guo J, Wang L, Wang L, Qian S, Zhang D,
Fang J and Pan J: Berberine protects human umbilical vein
endothelial cells against LPS-induced apoptosis by blocking
JNK-mediated signaling. Evid Based Complement Alternat Med.
2016:69839562016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wassmann S, Stumpf M, Strehlow K, Schmid
A, Schieffer B, Böhm M and Nickenig G: Interleukin-6 induces
oxidative stress and endothelial dysfunction by overexpression of
the angiotensin II type 1 receptor. Circ Res. 94:534–541. 2004.
View Article : Google Scholar
|
|
31
|
Ohta H, Wada H, Niwa T, Kirii H, Iwamoto
N, Fujii H, Saito K, Sekikawa K and Seishima M: Disruption of tumor
necrosis factor-alpha gene diminishes the development of
atherosclerosis in ApoE-deficient mice. Atherosclerosis. 180:11–17.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kumar S, Kim CW, Simmons RD and Jo H: Role
of flow-sensitive microRNAs in endothelial dysfunction and
atherosclerosis: Mechanosensitive athero-miRs. Arterioscler Thromb
Vasc Biol. 34:2206–2216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang X, Guo Y, Wang C and Yu H, Yu X and
Yu H: MicroRNA-142 3p Inhibits chondrocyte apoptosis and
inflammation in osteoarthritis by targeting HMGB1. Inflammation.
39:1718–1728. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choy JC, Granville DJ, Hunt DW and McManus
BM: Endothelial cell apoptosis: Biochemical characteristics and
potential implications for atherosclerosis. J Mol Cell Cardiol.
33:1673–1690. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Furnkranz A, Schober A, Bochkov VN,
Bashtrykov P, Kronke G, Kadl A, Binder BR, Weber C and Leitinger N:
Oxidized phospholipids trigger atherogenic inflammation in murine
arteries. Arterioscler Thromb Vasc Biol. 25:633–638. 2005.
View Article : Google Scholar
|
|
37
|
Stein O and Stein Y: Atheroprotective
mechanisms of HDL. Atherosclerosis. 144:285–301. 1999. View Article : Google Scholar : PubMed/NCBI
|
